APL-1401
Moderately to Severely Active Ulcerative Colitis
Not SpecifiedActive
Key Facts
Indication
Moderately to Severely Active Ulcerative Colitis
Phase
Not Specified
Status
Active
Company
About Asieris Pharmaceuticals
Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.
View full company profile